On December 2, Biocon Biologics announced that it had received FDA approval for Yesintek (ustekinumab-kfce), the sixth authorized biosimilar to Stelara (so far). The Yesintek approval assures Biocon Biologics that it will be able to launch its latest biosimilar in the middle of the pack, along with Fresenius Kabi, Samsung Bioepis, and Sandoz, no later … Continue reading Biocon Biologics Joins the Ustekinumab Fray With Yesintek